 SOUTH SAN FRANCISCO, Calif., March 16, 2021 GLOBE NEWSWIRE -- VistaGen Therapeutics NASDAQ: VTGN, a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system CNS disorders, today announced that Shawn Singh, VistaGens Chief Executive Officer, will participate in the following investor conferences in March: 